Highest-materiality recent filing
Nature's Miracle settles noteholder litigation for $575K; must reserve 222M shares
Settles $791K asserted indebtedness on four convertible notes for $575K via cash and conversion rights.
Nature's Miracle Holdings restates Q3 2025 financials due to omitted short-term loan
On April 13, 2026, management determined to preclude reliance on previously issued unaudited financials for Q3 2025.
President and director Zhiyi Zhang resigns; Frank Du appointed
Zhiyi Zhang resigned as President effective Feb 28, 2026, and from board Dec 31, 2025.
Issued 15,000,000 unregistered shares to Megaphoton CEO Jinlong Du; company to register shares by July 31, 2026.
Nature's Miracle increases authorized common stock from 100M to 1B shares
Certificate of Amendment filed Dec 4, 2025, raising authorized shares to 1,000,000,000.
Nature's Miracle raises $2M via Series D preferred; enters $3M note with CEO affiliate
Sold 500 Series D shares at $1k each ($500k) to Y.K. Capital; second $500k closing due by Oct 30, 2025; final $1M before Nasdaq/NYSE uplisting.
Nature's Miracle acquires Ohio property from CEO for $17.5M via preferred stock and convertible note
Buys Zak Properties LLC (owns 405 Madison Ave, Ohio) from CEO Tie Li's Big Lake Capital LLC for $17.5M.
Nature's Miracle enters four settlement agreements totaling ~$748k to resolve defaulted loans
Funders App settlement of $129,463 with payments starting July 23, 2025; original loan $110k.
Nature's Miracle issues $172,500 convertible note and 200,000 shares to FirstFire for $150,000
Net proceeds of $144,000 after $6,000 legal fee deduction; note matures in 12 months.
Nature's Miracle amends equity line; max per draw raised to $2M from $500k
Amended Equity Financing Agreement with GHS Investments increases per-Put maximum to $2,000,000.
Nature's Miracle converts $1.69M debt/wages into 12.96M shares at $0.1305
CEO Tie Li converted $673,476 unpaid wages into 5,160,739 shares; President Zhiyi Zhang converted $406,691 into 3,111,408 shares.
Nature's Miracle enters $20M equity line with GHS Investments; issues preferred shares
ELOC up to $20M over 24 months; purchase price at 80% of lowest trade in 10-day pricing period.
Nature's Miracle enters $2M convertible note with CEO-controlled Big Lake Capital
Up to $2M convertible note; initial $600K funded April 11, 2025, from Big Lake Capital (CEO James Li controls holder).
CFO Wenbing Chris Wang resigns effective Feb 13; George Yutuc continues as CFO
Wang resigned as CFO effective Feb 13, 2025, after only 5 weeks in role; mutual separation agreement signed.
Nasdaq panel decides to delist Nature's Miracle Holding for minimum equity non-compliance
Received delisting notice from Nasdaq Hearings Panel for failing to meet minimum shareholders' equity requirement under Listing Rule 5550(b)(1).
Nature's Miracle appoints Wenbing Chris Wang as CFO, replacing Daphne Y. Huang
Daphne Y. Huang resigned as CFO effective January 7, 2025.
Nature's Miracle raises $3M via Series A Preferred and warrants private placement
Sold 3,000 Series A Preferred shares with $3,000,000 stated value at a 10% discount ($2,700,000 purchase price).
Nature's Miracle enters $311K loan at 59.4% APR; pledges 311K shares as collateral
Loan of $311,000 with 51.64% interest rate, 59.4% APR, matures Jan 14, 2026.
Purchase price up to $5.32M for 90% of fully-diluted shares of Toronto-based J&Y Marigold.
Nature's Miracle appoints Daphne Huang as CFO, George Yutuc as COO
George Yutuc transitions from CFO to COO, effective Dec. 1, 2024.
NM Data invests up to $3M ($200K initial + $2.8M in 12 months) for 51% of Future Tech.
Nature's Miracle receives Nasdaq delisting notice; hearing Dec 17, 1-for-30 reverse split effective
Received Nasdaq notice for failure to maintain $1 minimum bid price; not eligible for additional compliance period; hearing Dec 17.
Nature's Miracle closes $3M public offering of units with warrants; net proceeds ~$2.5M
Offering of 25,133,631 units at $0.1118/unit and 1,700,000 pre-funded units at $0.1117/unit for gross proceeds of ~$3M.
Nasdaq determines to delist Nature's Miracle Holding common stock; company to appeal
Received delisting notice on Oct 24, 2024 for failure to regain compliance with Nasdaq's MVLS and MVPHS rules by Oct 23 deadline.
Nature's Miracle issues $101K convertible note at 14%; faces Nasdaq delisting deadlines
Issued $101,200 convertible promissory note with $13,200 OID to an accredited investor, closing Oct 14, 2024.
Nature's Miracle receives $2.14M trade payable forgiveness from insider-owned Uninet
Visiontech owed Uninet $2,713,073 as of June 30, 2024; Uninet cancels $2,135,573, leaving $577,500 payable.
Principal amount of $107,880 includes $14,880 original issue discount; total payback of $121,904 due in five monthly payments starting March 15, 2025.
Nature's Miracle issues $181,700 convertible note with 12% interest and default conversion discount
Net proceeds of $158,000 after $23,700 OID; repayable in 10 monthly payments of $20,350.40 ($203,504 total).
Nature's Miracle COO Darin Carpenter resigns, to provide project-based consulting
COO Darin Carpenter resigned effective July 31, 2024, and will transition to per-project consulting.
Nature's Miracle pays off $180K convertible note in full; terminates agreement
Paid $212,400 on July 30, 2024 to extinguish $180K convertible note plus accrued interest and fees.
Nature's Miracle raises $1.2M in public offering of 5M units at $0.24/unit
Offering of 5,000,000 units consisting of one share + one Series A warrant at $0.24/unit.
Nature's Miracle raises $180k via convertible note, warrants at $0.87 per share
Issued $180,000 convertible note with $27,500 OID; 12% interest, 12-month maturity.
Nature's Miracle enters $410K convertible note private placement at $0.442/share
Gross proceeds of $410,000 from four unsecured convertible notes with 12% annual interest and six-month maturity.
Nature's Miracle receives Nasdaq deficiency notice for minimum bid price
Deficiency letter received May 23, 2024 for failing to maintain $1.00 closing bid for 30 consecutive business days.
Nature's Miracle and Agrify mutually terminate planned merger due to unfavorable market conditions
Merger agreement terminated mutually on May 19, 2024; no termination or cancellation fees incurred.
Nature's Miracle (NMHI) signs definitive merger with Agrify (AGFY); 0.45x exchange ratio
Each Agrify share converts to 0.45 NMHI shares; Agrify shareholders to own ~30% of combined company.
On Apr 26, 2024, Nasdaq notified Nature's Miracle that its MVPHS fell below $15M for 30 consecutive business days.
Nature's Miracle to acquire Agrify in stock deal valued at ~$6.35M
AGFY shareholders get 0.45 NMHI per share; implied equity ~$6.35M using NMHI $0.93 close.
Nature's Miracle rings Nasdaq closing bell after business combination closes
Company rang the closing bell at Nasdaq Times Square studio on March 19, 2024.
Nature's Miracle completes de-SPAC merger with Lakeshore Acquisition II; begins trading on Nasdaq
Closed merger with Lakeshore Acquisition II on March 11, 2024; combined entity renamed Nature's Miracle Holding Inc.
On February 13, 2025, Wenbing Chris Wang resigned as Chief Financial Officer of Nature’s Miracle Holding Inc. (the “ Company ”), effective immediately.
On January 7, 2025, Daphne Y. Huang resigned as Chief Financial Officer of Nature’s Miracle Holding Inc. (the “Company”).
On January 7, 2025, the Board of Directors of the Company appointed Wenbing Chris Wang, effective January 7, 2025, as Chief Financial Officer of the Company.
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the Board became comprised of five individuals: Charles Hausman; Zhiyi (Jonathan) Zhang; David Sherman; Tie (James) Li; and Jon Montgomery.
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the Board became comprised of five individuals: Charles Hausman; Zhiyi (Jonathan) Zhang; David Sherman; Tie (James) Li; and Jon Montgomery.
the Board became comprised of five individuals: Charles Hausman; Zhiyi (Jonathan) Zhang; David Sherman; Tie (James) Li; and Jon Montgomery.
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the Board became comprised of five individuals: Charles Hausman; Zhiyi (Jonathan) Zhang; David Sherman; Tie (James) Li; and Jon Montgomery.
Max materiality 0.95 · Median 0.65 · Most common event other_material